Gland Pharma Limited — Q3 FY26
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,695.4 crore (+22% YoY) and adjusted EBITDA of INR 449 crore (+25% YoY), driven by broad-based growth a...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Cenexi break-even in Q3 FY26
Cenexi is expected to break even in Q3 FY26, supported by EUR 50 million quarterly revenue target and cost initiatives.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1